Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan.

ABSTRACT:

Introduction

This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.

Methods

A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.

Results

The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased trea

SUBMITTER: Igarashi A 

PROVIDER: S-EPMC12504044 | biostudies-literature | 2025 Oct-Dec

REPOSITORIES: biostudies-literature